Serina Therapeutics, Inc.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Serina Therapeutics, Inc. (NYSE American: SER) is a clinical-stage biotechnology company that develops proprietary POZ Platform polymer technology to create long-acting drug conjugates for neurological diseases, pain management, and other indications including RNA-based therapeutics and antibody-drug conjugates; its lead product candidate SER-252 (POZ-apomorphine) provides continuous dopaminergic stimulation via twice-weekly subcutaneous injection for advanced Parkinson's disease; additional candidates comprise SER-270 (POZ-VMAT2 inhibitor) for tardive dyskinesia, SER-214 (POZ-rotigotine) for early Parkinson's disease and restless leg syndrome, SER-227 for long-acting pain relief, and SER-228 for epilepsy; the POZ technology offers near-linear release kinetics, reduced immunogenicity versus PEG polymers, and versatile administration via IV, SC, or IM routes. Founded in 2006 and headquartered at 601 Genome Way, Suite 2001, Huntsville, Alabama, the company operates primarily in the United States with global clinical trial plans including Australia and pursues a 505(b)(2) regulatory pathway to accelerate development leveraging established molecules. Recent developments include securing up to $20 million in convertible note and warrant financing in September 2025 with an initial $5 million tranche drawn to fund the registrational Phase 1b trial of SER-252, submission of an IND application to the FDA and receipt of Human Research Ethics Committee approval in Australia for SER-252 with first patient dosing on track for Q4 2025, FDA alignment in August 2025 confirming the SER-252 trial design as registrational under 505(b)(2), advancement of SER-270 into development for tardive dyskinesia in July 2025, and launch of an enhanced corporate communications platform in October 2025.
Company News
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"
Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Sees Significant Decline in Short Interest
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
Seres Therapeutics' SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026